Halozyme and Skye partner on obesity drug delivery technology

Halozyme Therapeutics Inc. (NASDAQ: HALO) and Skye Bioscience Inc. (NASDAQ: SKYE) entered into a global collaboration and license agreement in December 2025 to develop a subcutaneous formulation of nimacimab for obesity treatment using Halozyme's ENHANZE drug delivery technology.

The agreement allows Skye to use ENHANZE technology to evaluate higher doses of nimacimab through larger injection volumes administered subcutaneously. Skye will make milestone payments tied to development and commercialization achievements, while Halozyme will receive mid-single digit royalties on net sales of nimacimab developed with ENHANZE for at least 10 years.

"Our collaboration with Skye Bioscience expands the reach of our ENHANZE technology into the growing obesity market," said Dr. Helen Torley, President and Chief Executive Officer of Halozyme.

Skye plans to initiate a Phase 2b clinical trial for nimacimab with ENHANZE in mid-2026. The study will assess nimacimab alone and in combination with GLP-1 receptor agonists for obesity treatment.

"To fully evaluate nimacimab's potential, we need to test higher doses and we need a practical way to deliver them subcutaneously," said Punit Dhillon, President and Chief Executive Officer of Skye. "Partnering with Halozyme to co-formulate nimacimab with ENHANZE gives us a validated approach to evaluate multiple dose-ranging strategies."

Nimacimab is a negative allosteric modulating antibody that peripherally inhibits CB1. Skye is currently conducting a Phase 2a clinical trial in obesity for nimacimab, which includes assessment of the combination with GLP-1 receptor agonists.

ENHANZE technology uses the proprietary enzyme rHuPH20 to facilitate subcutaneous delivery of injected drugs and fluids. The technology has been used in ten commercialized products across over 100 global markets and is licensed to pharmaceutical companies including Roche, Takeda, Pfizer, Janssen, and others.

You May Also Be Interested In

• Cavitation Technologies agrees to $35M tender offer from Luxembourg firm
• NewGenIVF exchanges convertible notes with institutional investor
• RedCloud signs 3-year Argentina deal, forecasting $20m revenue